The outlook of companies tied to flagship drugs like Viagra presents a complex investment picture. While the initial rise of copyright, fueled by Viagra's unprecedented popularity, generated substantial returns, the loss of exclusivity in key markets has introduced substantial risk . Investors are now assessing the impact of lower-cost alternatives